Results 51 to 60 of about 3,831 (231)

Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation

mSphere, 2023
To evaluate the resistance mechanisms among Pseudomonas aeruginosa clinical isolates exhibiting meropenem (MEM) MIC values higher than meropenem-vaborbactam (MEV). P.
Mariana Castanheira, Timothy B. Doyle, Cory M. Hubler, Sean DeVries, Dee Shortridge   +4 more
doaj   +1 more source

Genomic and molecular characterisation of a Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam [PDF]

Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +2 more sources

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring

Antibiotics, 2023
Meropenem (MRP)-Vaborbactam (VBR) is a novel beta-lactam/beta-lactamase inhibitor used for the management of difficult-to-treat Gram-negative infections.
Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea   +6 more
doaj   +1 more source

Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study [PDF]

, 2022
Objectives To explore the real-life performance of meropenem/vaborbactam for treating serious KPC-producing Klebsiella pneumoniae infections, including those resistant to ceftazidime/avibactam.
Raffaelli, Francesca, Farese, Alberto, Fabbiani, Massimiliano, Tiseo, Giusy, De Pascale, Gennaro, Viale, Pierluigi, De Rosa, Francesco Giuseppe, Losito, Angela Raffaella, Bassetti, Matteo, Cascio, Antonio, Tumbarello, Mario, Oliva, Alessandra, Montagnani, Francesca, Spanu, Teresa, Morelli, Paola, Pascale, Renato, Venditti, Mario, Del Giacomo, Paola, Falcone, Marco, Giacobbe, Daniele Roberto, Meschiari, Marianna, Vargas, Joel, Signorini, Liana, Mussini, Cristina   +23 more
core   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

METHOD DEVELOPMENT AND VALIDATION FOR MEROPENEMAND VABORBACTAM BY RP-HPLC METHOD

, 2023
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in Tablet dosage form. Chromatogram was run through Inertsil ODS C185mm (4.6 x 250mm).
D.Vaishnavi, Dr V.Kiran Kumar
core   +1 more source

Differential Scanning Fluorimetry (DSF)/thermal shift assay probing protein stabilization of P. aeruginosa PBP3 by vaborbactam.

, 2021
The rate of change in SYPRO orange fluorescence is plotted versus temperature for PBP3 in the presence of varying concentrations of vaborbactam. Duplicate measured Tm values are as follows: PBP3 (with DMSO): 47.2 and 47.8°C; PBP3 with 0.5 mM vaborbactam (
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

Superimposition of vaborbactam-bound PBP3 onto KPC-2 β-lactamase bound vaborbactam structure.

, 2021
The colors and representation of PBP3 and its bound vaborbactam are as in Fig 6A. KPC-2 (PDBid 6V7I is shown in green backbone trace and green carbon atoms; its bound vaborbactam is depicted in ball-and-stick with green carbon atoms. Shifts in the β3 and
Vijay Kumar (377076), Jeeda Ismail (11570566), Focco van den Akker (158508), Shreya Agarwal (774270), Samantha L. Viviani (11570563), Robert A. Bonomo (188763)   +5 more
core   +1 more source

In vitro susceptibility of nonfermenting Gram-negative rods tomeropenem–vaborbactam and delafloxacin Suppl. Table 1

, 2023
Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with
Thomas Guillard (12633958), Amelie Bosphore (14549900), Antoine Roux (14549894), Eric Farfour (11021923), Corentine Alauzet (14549885), Lise Cremet (14549888), Louise Ruffier d’Epenoux (14549879), Sophie Moussalih (14549891), Marc Vasse (335648), Sylvie C de Verdiere (14549897), Stephane Corvec (14549903), Anaelle Muggeo (14549882)   +11 more
core   +1 more source